@inproceedings{inproceedings, title  = {{Weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1106 }},

 year = {{2015}},

 month = {{5}},

 author = {{Yardley DA and Cortes J and Coleman RE and Conte PF and Brufsky A and O'Shaughnessy J and Wright GLS and Eakle JF and Wilks S and Shtivelband M and Young RR et al}},

 doi = {{10.1200/jco.2015.33.15_suppl.tps1106}},

 volume = {{33}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{TPS1106-TPS1106}},

 note = {{Accessed on 2025/10/10}}}